<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867880</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-CL-011</org_study_id>
    <nct_id>NCT00867880</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study Of Ibuprofen Injection (IVIb) In Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Crossover Study of the Pharmacokinetics, Safety and Tolerability of Ibuprofen Inejction (IVIb) In Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetic profile of a single
      dose of IVIb administered over 5-7 minutes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic profile of a single dose of IVIb administered over 5-7 minutes.</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of a single dose of IVIb in healthy adult participants.</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVIb</intervention_name>
    <description>800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers between the ages of 18 and 65 years (at the time of consent).

        Exclusion Criteria:

          -  Participants lacking good venous access in both arms.

          -  History of allergy or hypersensitivity to NSAIDs or any component of intravenous
             ibuprofen.

          -  Have never taken aspirin or ibuprofen

          -  History of abuse of alcohol or other drugs in the 2 months before CTM administration.

          -  Have used prescription drugs (not including oral contraceptives) within 14 days before
             CTM administration or have used aspirin within one week before CTM administration or
             over-the-counter pain relievers (NSAIDs or acetaminophen) within 3 days before CTM
             administration.

          -  Have taken investigational drugs within 30 days before CTM administration.

          -  Have donated blood or blood products within 30 days before CTM administration.

          -  Be pregnant or nursing.

          -  Have had breast cancer.

          -  Have a clinically significant laboratory test

          -  Presence or history of the following conditions: asthma, bleeding tendency,
             hypertension, heart failure, peptic ulcer disease, inflammatory bowel disease, or any
             other gastrointestinal disorder, renal or hepatic disease..

          -  Have a calculated creatinine clearance (estimated by means of the Cockcroft-Gault
             equation) of &lt; 75mL/min

          -  Inability to understand the requirements of the study. Participants must be willing to
             provide written informed consent (as evidenced by signature on an informed consent
             document approved by an Institutional Review Board [IRB]), and agree to abide by the
             study restrictions.

          -  Refusal to provide written authorization for use and disclosure of protected health
             information

          -  Be otherwise unsuitable for the study, in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Milne, Associate Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Pharmaceutical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Pharmaceutical Research</name>
      <address>
        <city>Underdale</city>
        <state>South Australia</state>
        <zip>5032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>To evaluate the Pharmacokinetic Profile of IVIb</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

